EMEA-003555-PIP01-23 - paediatric investigation plan
alrefimotide
tapderimotide
riletamotide
PIPHuman
Key facts
- Active Substance
- alrefimotide
- tapderimotide
- riletamotide
- Therapeutic area
- Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Decision number
- P/0140/2024
- PIP number
- EMEA-003555-PIP01-23
- Pharmaceutical form(s)
- All pharmaceutical forms
- Condition(s) / indication(s)
- Treatment of mesothelioma
- Route(s) of administration
- All routes of administration
- Contact for public enquiries
Ultimovacs ASA
E-mail: mail@ultimovacs.com
Tel.: +47 41380080- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date